Hypothermia_NN and_CC neurologic_JJ outcome_NN in_IN patients_NNS following_VBG cardiac_JJ arrest_NN :_: should_MD we_PP be_VB hot_JJ to_TO cool_VB off_RP our_PP$ patients_NNS ?_SENT Abstract_NN |_SYM Hypothermia_NP as_IN a_DT protectant_NN of_IN neurologic_JJ function_NN in_IN the_DT treatment_NN of_IN cardiac_JJ arrest_NN patients_NNS ,_, although_IN not_RB a_DT new_JJ concept_NN ,_, is_VBZ now_RB supported_VBN by_IN two_CD recent_JJ randomized_VBN ,_, prospective_JJ clinical_JJ trials_NNS ._SENT The_DT basic_JJ science_NN research_NN in_IN support_NN of_IN the_DT effects_NNS of_IN hypothermia_NN at_IN the_DT cellular_JJ and_CC animal_JJ levels_NNS is_VBZ extensive_JJ ._SENT The_DT process_NN of_IN cooling_VBG for_IN cerebral_JJ protection_NN holds_VBZ potential_JJ promise_NN for_IN human_JJ resuscitation_NN efforts_NNS in_IN multiple_JJ realms_NNS ._SENT It_PP appears_VBZ that_IN ,_, at_IN least_JJS ,_, those_DT patients_NNS who_WP suffer_VBP a_DT witnessed_VBN cardiac_JJ arrest_NN with_IN ventricular_JJ fibrillation_NN and_CC early_JJ restoration_NN of_IN spontaneous_JJ circulation_NN ,_, such_JJ as_IN those_DT who_WP were_VBD included_VBN in_IN the_DT European_JJ and_CC Australian_JJ trials_NNS (_( discussed_VBN here_RB )_) ,_, should_MD be_VB considered_VBN for_IN hypothermic_JJ therapy_NN ._SENT cardiac_JJ arrest_NN ,_, cerebral_JJ protection_NN ,_, cooling_VBG ,_, hypothermia_NN ,_, resuscitation_NN ,_, In_IN two_CD recent_JJ issues_NNS of_IN New_NP England_NP Journal_NP of_IN Medicine_NP ,_, studies_NNS using_VBG hypothermia_NN in_IN patients_NNS following_VBG cardiac_JJ arrest_NN (_( CA_NP )_) to_TO improve_VB neurologic_JJ outcome_NN were_VBD presented_VBN and_CC debated_VBN ._SENT Not_RB a_DT new_JJ issue_NN ,_, having_VBG first_RB surfaced_VBN in_IN the_DT 1950s_NNS ,_, hypothermia_NN as_IN a_DT treatment_NN strategy_NN is_VBZ potentially_RB promising_VBG as_IN a_DT mechanism_NN to_TO curtail_VB neurologic_JJ injury_NN in_IN specific_JJ ,_, although_IN not_RB fully_RB defined_VBN ,_, patient_JJ situations_NNS ._SENT As_IN resuscitative_JJ measures_NNS have_VBP expanded_VBN ,_, the_DT need_NN for_IN options_NNS to_TO improve_VB neurologic_JJ function_NN after_IN CA_NP is_VBZ of_IN paramount_JJ importance_NN ._SENT Two_CD recent_JJ trials_NNS reported_VBN by_IN Holzer_NP and_CC colleagues_NNS (_( conducted_VBN in_IN Europe_NP )_) and_CC Bernard_NP and_CC coworkers_NNS (_( conducted_VBN in_IN Australia_NP )_) yielded_VBD statistically_RB significant_JJ ,_, positive_JJ outcomes_NNS ._SENT Our_PP$ goals_NNS in_IN the_DT present_JJ commentary_NN are_VBP to_TO affirm_VB the_DT viability_NN of_IN hypothermia_NN as_IN a_DT therapeutic_JJ intervention_NN ,_, to_TO evaluate_VB the_DT European_JJ and_CC Australian_JJ trials_NNS ,_, and_CC to_TO explore_VB the_DT potential_NN of_IN hypothermia_NN as_IN a_DT treatment_NN modality_NN ._SENT Table_NP 1_CD |_SYM Comparison_NN of_IN two_CD recent_JJ trials_NNS of_IN hypothermia_NN in_IN cardiac_JJ arrest_NN the_DT science_NN :_: Data_NNS support_VBP the_DT contention_NN that_IN hypothermia_NN is_VBZ not_RB only_RB biologically_RB plausible_JJ as_IN a_DT therapy_NN but_CC also_RB improves_VBZ neurologic_JJ outcome_NN in_IN animals_NNS and_CC ,_, now_RB ,_, in_IN humans_NNS ._SENT The_DT timing_NN and_CC duration_NN of_IN treatment_NN ,_, as_RB well_RB as_IN the_DT degree_NN of_IN hypothermia_NN ,_, were_VBD shown_VBN to_TO impact_VB on_IN efficacy_NN and_CC outcome_NN ._SENT Given_VBN different_JJ mechanistic_JJ etiologies_NNS for_IN neurologic_JJ injury_NN ,_, different_JJ diseases_NNS have_VBP been_VBN shown_VBN to_TO respond_VB variably_RB to_TO treatment_NN with_IN hypothermia_NN ._SENT Finally_RB ,_, use_NN of_IN mild_JJ hypothermia_NN has_VBZ refuted_VBN the_DT previously_RB expected_VBN side-effect_NN profile_NN of_IN hypothermia_NN ._SENT The_DT basis_NN for_IN the_DT use_NN of_IN hypothermia_NN in_IN cerebral_JJ protection_NN (_( i.e._FW to_TO attenuate_VB the_DT effects_NNS of_IN cerebral_JJ ischemia_NN )_) is_VBZ supported_VBN by_IN animal_JJ studies_NNS ._SENT Cerebral_JJ ischemia_NN causes_VBZ early_JJ and_CC late_JJ effects_NNS ._SENT Energy_NN failure_NN ,_, ion_NN pump_NN failure_NN ,_, and_CC release_NN of_IN free_JJ radicals_NNS and_CC excitotoxic_JJ agents_NNS occur_VBP early_RB ,_, whereas_IN inflammatory_JJ mechanisms_NNS and_CC release_NN of_IN stress-related_JJ proteins_NNS progress_NN over_IN hours_NNS after_IN reperfusion_NN ._SENT Excitotoxicity_NN and_CC free_JJ radical_JJ formation_NN promote_VB cell_NN damage_NN in_IN ischemic_JJ tissue_NN early_RB after_IN reperfusion_NN ._SENT Glutamate_NN levels_NNS --_: a_DT major_JJ component_NN of_IN the_DT excitotoxic_JJ response_NN --_: decrease_VB during_IN hypothermic_JJ treatment_NN of_IN ischemia_NN in_IN rabbits_NNS ._SENT By_IN attenuating_VBG release_NN of_IN glutamate_NN ,_, the_NP '_POS death_NN funnel_NN '_'' of_IN N-methyl-D-aspartate_JJ receptor_NN stimulation_NN (_( opening_VBG ion_NN channels_NNS ,_, allowing_VBG influx_NN of_IN calcium_NN ,_, and_CC thereby_RB producing_VBG the_DT cascade_NN of_IN second_JJ messengers_NNS that_WDT activate_VBP kinases_NNS and_CC proteases_NNS ,_, leading_VBG to_TO cellular_JJ destruction_NN )_) is_VBZ lessened_VBN ._SENT Later_JJR responses_NNS to_TO reperfusion_NN following_VBG ischemia_NN include_VBP the_DT production_NN of_IN stress-related_JJ proteins_NNS ,_, such_JJ as_IN heat_NN shock_NN proteins_NNS ._SENT These_DT proteins_NNS ,_, in_IN turn_NN ,_, are_VBP believed_VBN to_TO influence_VB other_JJ gene_NN products_NNS ._SENT Elevations_NNS in_IN heat_NN shock_NN protein-70_NN in_IN the_DT hippocampus_NN are_VBP blunted_VBN by_IN hypothermia_NN ._SENT Additionally_RB ,_, arachidonic_JJ acid_JJ products_NNS may_MD be_VB involved_VBN in_IN an_DT inflammatory_JJ cascade_NN ,_, affecting_VBG cell_NN survival_NN ._SENT In_IN gerbils_NNS ,_, hypothermia_NN decreases_VBZ levels_NNS of_IN leukotriene_NN B4_NP --_: a_DT substance_NN linked_VBN to_TO cerebral_JJ edema_NN ._SENT Safar_NP and_CC Leonov_NP ,_, along_RB with_IN their_PP$ research_NN groups_NNS ,_, conducted_VBN elegent_JJ animal_NN studies_NNS in_IN the_DT 1980s_NNS and_CC 1990s_NNS ,_, verifying_VBG improvement_NN in_IN outcome_NN when_WRB hypothermia_NN is_VBZ used_VBN as_IN treatment_NN in_IN cardiac_JJ arrest_NN models_NNS ,_, both_CC with_IN functional_JJ ratings_NNS and_CC electromyographic_JJ improvement_NN ._SENT Weinrauch_NP and_CC colleagues_NNS demonstrated_VBD that_DT hypothermia_NN to_TO 30_CD and_CC 34C_JJ ,_, achieved_VBN by_IN a_DT combination_NN of_IN partial_JJ bypass_NN flow_NN and_CC surface_NN cooling_NN performed_VBD immediately_RB after_IN cardiac_JJ arrest_NN ,_, improves_VBZ both_DT neurologic_JJ deficit_NN score_NN and_CC histologic_JJ damage_NN scores_NNS in_IN dogs_NNS ._SENT Hypothermia_NN begun_VBN hours_NNS after_IN the_DT initial_JJ insult_NN is_VBZ not_RB likely_JJ to_TO affect_VB the_DT initial_JJ ischemic_JJ processes_NNS ._SENT Thus_RB ,_, early_JJ hypothermia_NN is_VBZ likely_JJ to_TO be_VB more_RBR effective_JJ than_IN delayed_JJ hypothermia_NN ._SENT In_IN a_DT rat_NN model_NN ,_, delays_NNS of_IN 15_CD min_NN and_CC 30_CD min_NN preserved_VBD the_DT beneficial_JJ effect_NN of_IN hypothermia_NN ,_, but_CC with_IN delays_NNS of_IN 45_CD min_NN there_RB was_VBD no_DT attenuation_NN of_IN infarct_NN volume_NN ._SENT In_IN dogs_NNS ,_, delaying_VBG hypothermia_NN by_IN 15_CD min_NN obscured_VBD the_DT benefit_NN in_IN functional_JJ outcome_NN as_IN compared_VBN with_IN that_DT with_IN immediate_JJ hypothermia_NN ;_: however_RB ,_, it_PP might_MD have_VB attenuated_VBN tissue_NN damage_NN ,_, as_RB detected_VBN histologically_RB ._SENT In_IN addition_NN to_TO initiation_NN timing_NN ,_, duration_NN has_VBZ been_VBN investigated_VBN ._SENT Increasing_VBG the_DT duration_NN of_IN hypothermia_NN appears_VBZ to_TO decrease_VB infarct_NN size_NN ._SENT In_IN a_DT rat_NN model_NN ,_, hypothermia_NN with_IN durations_NNS of_IN 3_CD and_CC 4_CD hours_NNS was_VBD superior_JJ to_TO 2_CD hours_NNS in_IN terms_NNS of_IN effect_NN on_IN infarct_NN volume_NN ,_, whereas_IN 1_CD hour_NN appeared_VBD ineffective_JJ ._SENT An_DT early_RB reported_VBN human_JJ series_NN by_IN Williams_NP and_CC Spence_NP at_IN Johns_NP Hopkins_NP in_IN 1959_CD employed_VBN durations_NNS from_IN 24_CD to_TO 72_CD hours_NNS ,_, with_IN good_JJ outcomes_NNS at_IN both_DT extremes_NNS ._SENT the_DT current_JJ state_NN :_: Although_IN many_JJ models_NNS of_IN neuroprotection_NN in_IN traumatic_JJ brain_NN injury_NN have_VBP shown_VBN a_DT positive_JJ correlation_NN between_IN hypothermia_NN and_CC outcome_NN ,_, several_JJ studies_NNS in_IN humans_NNS have_VBP failed_VBN to_TO affirm_VB this_DT ._SENT In_IN a_DT recent_JJ meta-analysis_NN of_IN seven_CD clinical_JJ trials_NNS conducted_VBN from_IN 1993_CD to_TO 2001_CD ,_, it_PP was_VBD concluded_VBN that_IN hypothermia_NN is_VBZ not_RB beneficial_JJ in_IN the_DT management_NN of_IN severe_JJ head_NN injury_NN ._SENT Those_DT authors_NNS did_VBD ,_, however_RB ,_, concede_VBP that_IN further_JJR studies_NNS are_VBP '_POS justified_JJ and_CC urgently_RB needed_VBN '_'' ._SENT Design_NN problems_NNS exist_VBP in_IN both_DT of_IN the_DT two_CD new_JJ trials_NNS of_IN hypothermia_NN for_IN CA_NP ,_, namely_RB potential_JJ bias_NN (_( the_DT treating_VBG physicians_NNS were_VBD unblinded_JJ )_) ,_, the_DT sample_NN sizes_NNS were_VBD small_JJ ,_, and_CC some_DT of_IN the_DT treatment_NN protocol_NN aspects_NNS were_VBD different_JJ (_( such_JJ as_IN the_DT time_NN of_IN initiation_NN of_IN hypothermia_NN [_SYM in_IN the_DT field_NN versus_CC hospital_NN ]_SYM and_CC duration_NN of_IN hypothermia_NN [_SYM 12_CD versus_CC 24_CD hours_NNS ]_SYM )_) ._SENT Critics_NNS of_IN those_DT studies_NNS have_VBP expressed_VBN concerns_NNS over_IN several_JJ issues_NNS :_: the_DT hypothermia_NN and_CC normothermia_NN groups_NNS may_MD not_RB have_VB been_VBN well_RB matched_VBN ;_: the_DT sample_NN sizes_NNS were_VBD small_JJ ;_: the_DT subgroups_NNS of_IN patients_NNS with_IN CA_NP analyzed_VBD were_VBD small_JJ percentages_NNS of_IN the_DT total_JJ number_NN of_IN CAs_NN (_( 13_CD --_: 19_CD %_NN )_) ;_: and_CC side_NN effects_NNS of_IN hypothermia_NN can_MD be_VB extensive_JJ ._SENT The_DT responses_NNS of_IN the_DT principal_JJ investigators_NNS to_TO those_DT issues_NNS indicate_VBP that_IN both_DT groups_NNS were_VBD well_RB matched_VBN ,_, with_IN median_JJ Glasgow_NP Coma_NP Scale_NP scores_NNS of_IN 3_CD in_IN both_DT groups_NNS and_CC interquartile_JJ ranges_NNS from_IN 3_CD to_TO 4_CD or_CC 5_CD ._SENT They_PP also_RB point_VBP out_RP that_IN ,_, although_IN the_DT subgroup_NN of_IN CA_NP in_IN their_PP$ studies_NNS was_VBD a_DT small_JJ percentage_NN of_IN the_DT whole_JJ CA_NP population_NN ,_, future_JJ studies_NNS may_MD show_VB that_DT hypothermia_NN could_MD confer_VB a_DT benefit_NN in_IN other_JJ subgroups_NNS ._SENT Finally_RB ,_, the_DT two_CD clinical_JJ trials_NNS from_IN Europe_NP and_CC Australia_NP showed_VBD no_DT statistical_JJ difference_NN in_IN side-effect_NN profiles_NNS between_IN the_DT normothermic_JJ and_CC the_DT hypothermic_JJ groups_NNS ._SENT Potential_JJ side_NN effects_NNS of_IN hypothermia_NN such_JJ as_IN arrhythmias_NNS ,_, coagulopathies_NNS ,_, infection_NN ,_, electrolyte_NN disturbance_NN ,_, and_CC hypothermia-induced_JJ polyuria_NN were_VBD previously_RB reported_VBN in_IN the_DT literature_NN ._SENT In_IN mild_JJ hypothermia_NN ,_, it_PP appears_VBZ that_IN the_DT incidence_NN and_CC severity_NN of_IN side_NN effects_NNS is_VBZ diminished_VBN ._SENT For_IN example_NN ,_, the_DT development_NN of_IN arrhythmia_NN is_VBZ temperature_NN related_JJ ;_: temperatures_NNS below_IN 30C_JJ are_VBP more_RBR likely_JJ to_TO cause_VB serious_JJ arrhythmias_NNS such_JJ as_IN ventricular_JJ fibrillation_NN ._SENT Additionally_RB ,_, some_DT of_IN the_DT complications_NNS experienced_VBN in_IN early_JJ studies_NNS of_IN hypothermia_NN can_MD be_VB negated_VBN using_VBG modern_JJ intensive_JJ care_NN monitoring_NN and_CC treatment_NN plans_NNS ._SENT Despite_IN the_DT study_NN flaws_NNS described_VBD above_RB ,_, outcomes_NNS show_VBP agreement_NN with_IN the_DT relative_JJ percentages_NNS presented_VBN in_IN other_JJ studies_NNS ._SENT In_IN Fig._NN the_DT numbers_NNS of_IN favorable_JJ outcomes_NNS from_IN the_DT normothermia_NN arms_NNS of_IN the_DT two_CD trials_NNS can_MD be_VB seen_VBN to_TO approximate_VB closely_RB those_DT of_IN other_JJ studies_NNS over_IN time_NN ._SENT Also_RB ,_, despite_IN the_DT small_JJ size_NN of_IN the_DT samples_NNS ,_, both_CC studies_NNS achieved_VBD statistical_JJ significance_NN ._SENT Figure_NP 1_CD |_SYM Difference_NN in_IN hypothermia_NN versus_CC normothermia_NN :_: study_NN comparisons_NNS ._SENT Difference_NN in_IN hypothermia_NN versus_CC normothermia_NN :_: study_NN comparisons_NNS ._SENT Shown_VBN is_VBZ the_DT percentage_NN favorable_JJ outcome_NN ,_, or_CC survival_NN to_TO discharge_VB ,_, compared_VBN among_IN the_DT two_CD recent_JJ studies_NNS of_IN hypothermia_NN as_IN treatment_NN following_VBG cardiac_JJ arrest_NN ,_, a_DT small_JJ series_NN from_IN 1959_CD (_( 27_CD patients_NNS ,_, 12_CD treated_VBN with_IN hypothermia_NN )_) ,_, and_CC three_CD nonhypothermic_JJ series_NN ._SENT The_DT right-most_JJ three_CD bars_NNS are_VBP zero_CD within_IN the_DT hypothermia_NN group_NN because_IN they_PP represent_VBP studies_NNS that_WDT were_VBD not_RB designed_VBN to_TO test_VB hypothermia_NN as_IN an_DT intervention_NN ._SENT Visual_JJ comparison_NN reveals_VBZ the_DT closeness_NN of_IN new_JJ data_NNS from_IN the_DT two_CD trials_NNS with_IN respect_NN to_TO the_DT other_JJ studies_NNS ._SENT *_SYM ,_, ,_, These_DT studies_NNS were_VBD not_RB hypothermic_JJ trials_NNS ;_: rather_RB ,_, they_PP are_VBP included_VBN here_RB to_TO give_VB a_DT perspective_NN on_IN relative_JJ discharge_NN statistics_NNS following_VBG cardiac_JJ arrest_NN from_IN other_JJ series_NN ._SENT our_PP$ opinion_NN :_: The_DT evidence_NN suggests_VBZ that_IN hypothermia_NN reduces_VBZ neurologic_JJ injury_NN in_IN animals_NNS and_CC humans_NNS through_IN several_JJ intricate_JJ biochemical_JJ and_CC physiologic_JJ mechanisms_NNS ,_, most_JJS of_IN which_WDT we_PP are_VBP only_RB beginning_VBG to_TO understand_VB ._SENT The_DT European_JJ and_CC Australian_JJ trials_NNS both_CC show_VBP statistically_RB significant_JJ and_CC clinically_RB relevant_JJ improvement_NN ._SENT Thus_RB ,_, we_PP believe_VBP that_IN the_DT time_NN has_VBZ come_VBN to_TO conduct_VB extensive_JJ ,_, large_JJ ,_, multicenter_NN trials_NNS using_VBG hypothermia_NN to_TO provide_VB neurologic_JJ protection_NN after_IN cardiac_JJ arrest_NN ._SENT The_DT trials_NNS should_MD include_VB broader_JJR populations_NNS of_IN CA_NP patients_NNS (_( i.e._FW not_RB limited_JJ to_TO ventricular_JJ fibrillation_NN arrest_NN )_) and_CC larger_JJR study_NN populations_NNS ,_, should_MD explore_VB a_DT quicker_JJR method_NN of_IN cooling_VBG (_( such_JJ as_IN intravascular_JJ cooling_NN catheters_NNS )_) ,_, and_CC should_MD attempt_VB to_TO establish_VB an_DT effective_JJ duration_NN of_IN therapy_NN (_( 12_CD versus_IN 24_CD hours_NNS versus_IN other_JJ durations_NNS )_) ._SENT Given_VBN the_DT high_JJ incidence_NN of_IN CA_NP and_CC the_DT speed_NN with_IN which_WDT patients_NNS typically_RB come_VBP to_TO medical_JJ attention_NN ,_, the_DT numbers_NNS of_IN patients_NNS available_JJ for_IN recruitment_NN should_MD allow_VB a_DT reasonable_JJ study_NN completion_NN time_NN ._SENT Additionally_RB ,_, if_IN ,_, as_IN expected_VBN ,_, the_DT larger_JJR trials_NNS support_VBP the_DT findings_NNS of_IN the_DT recent_JJ smaller_JJR trials_NNS ,_, then_RB this_DT will_MD provide_VB the_DT impetus_NN to_TO examine_VB other_JJ causes_NNS of_IN hypoxic/ischemic_JJ injury_NN ,_, such_JJ as_IN acute_JJ ischemic_JJ stroke_NN ._SENT Until_IN such_JJ larger_JJR trials_NNS are_VBP conducted_VBN ,_, it_PP is_VBZ our_PP$ opinion_NN that_IN the_DT evidence_NN ,_, provided_VBN in_IN prior_JJ feasibility/safety_NN studies_NNS as_RB well_RB as_IN in_IN the_DT combined_JJ European_JJ and_CC Australian_JJ trials_NNS reported_VBD earlier_RBR this_DT year_NN ,_, supports_VBZ employing_VBG mild_JJ hypothermic_JJ therapy_NN in_IN the_DT patient_JJ populations_NNS studied_VBN (_( those_DT who_WP have_VBP suffered_VBN witnessed_VBN ventricular_JJ fibrillation_NN arrest_NN ,_, restoration_NN of_IN spontaneous_JJ circulation_NN ,_, etc._FW )_) ._SENT TLS_NP and_CC TPB_NP have_VBP previously_RB conducted_VBN trials_NNS involving_VBG temperature_NN control_NN for_IN neurologic_JJ conditions_NNS other_JJ than_IN cardiac_JJ arrest_NN ._SENT CA_MD =_SYM cardiac_JJ arrest_NN ._SENT 